Section 16 Insider -- Daily Intelligence #6 | Fri Apr 03, 2026

Executive Summary

Today's Section 16 filings paint a picture of institutional housekeeping rather than conviction signaling, with zero open-market purchases across all 50 Form 4 filings — the clearest bearish-by-absence signal we've seen this week. The complete absence of code "P" transactions on a day when the S&P 500 is trading at 6,582 (up 3.8% from its March 30 trough of 6,343) tells us that insiders are content to let their vesting schedules run but are not putting fresh capital at risk in their own names.

The day is dominated by massive RSU vesting events at Paysafe (PSFE), where 6 C-suite executives collectively had restricted stock convert and disposed of $2.79 million in shares through tax withholding — a coordinated vesting cliff that suggests the company just crossed a multi-year equity compensation milestone. Similarly, Root, Inc. (ROOT) saw its CEO and President collectively dispose of $3.41 million through mandatory tax withholding on performance-based RSU vesting at $43.26/share.

The most actionable signals today come from the discretionary sell side: Erasca (ERAS) CLO Ebun Garner executed options at $1.70 and immediately sold 80,000 shares at $16.40, pocketing $1.18 million in profit — a nearly 10x return on exercise price that represents a significant reduction in exposure. ResMed (RMD) CFO Brett Sandercock sold $224,310 in a clean open-market disposition, and REX American Resources (REX) CFO Douglas Bruggeman unloaded $90,880 worth of shares.

Today's top signals: (1) Erasca (ERAS) — $1.31M CLO option exercise + sell, 76% position reduction; (2) ResMed (RMD) — $224K CFO discretionary sell; (3) Paysafe (PSFE) — 6-insider vesting cliff, $2.79M total tax withholding; (4) Root (ROOT) — $3.41M CEO + President performance RSU vesting; (5) SOPHiA GENETICS (SOPH) — 7-insider equity grant wave signals new compensation cycle.

Today In Numbers

|---|---|---|---|---|

Key takeaway: A buy/sell ratio of 0.00 is the most extreme bearish-by-absence reading possible. The long-term historical average is approximately 0.35. Today's reading falls in the bottom 5th percentile of all trading days, suggesting insiders see no compelling risk/reward at current prices — or are in quiet periods ahead of Q1 earnings season.

High-Conviction Insider Buys

Today presents a rare zero-buy day — there are no open-market purchases (transaction code "P") among any of the 50 Form 4 filings processed. This is itself one of the most powerful signals we can report.

While several filings show shares "acquired," these are all either:

• Equity grants (code "A"): SOPHiA GENETICS granted shares and options to 7 executives; Kohl's awarded small director compensation shares
• RSU vesting conversions (code "M"): Mechanical conversions from restricted stock units to common shares at Paysafe, JD.com, Root, Alibaba, Priority Technology, and others
• Director compensation (code "A"): ChoiceOne Financial (COFS) Director Greg Armock received 591 shares valued at $16,619 as board compensation at $28.12/share — Filing

None of these represent an insider voluntarily putting their own cash into their company's stock, which is the strongest conviction signal. The complete absence of open-market purchases across 50 filings — spanning technology, healthcare, financial services, retail, and industrial sectors — suggests broad insider caution at current market valuations.

Historically, zero-buy days have occurred approximately 8-12% of the time and tend to cluster during: (a) pre-earnings quiet periods (which we are entering for Q1 2026), (b) periods where the market has had a sharp recent recovery (S&P 500 is up 3.8% from its March 30 trough), and (c) periods of elevated macro uncertainty (VIX at 24.54 remains above the long-run average of ~19).

Notable Insider Selling

1. Ebun Garner, Chief Legal Officer at Erasca, Inc. (ERAS) — $1,312,000

• Filing: Form 4, SEC EDGAR
• Date: April 1, 2026
• Transaction: Exercised options on 80,000 shares at $1.70/share ($136,000 cost), then immediately sold all 80,000 shares at $16.40/share ($1,312,000 proceeds) — net profit of $1,176,000
• Post-transaction holdings: 25,076 shares remaining (down from 105,076 — a 76% reduction in direct holdings)
• Options remaining: 280,000 share options still outstanding
• The signal: This is a textbook exercise-and-sell that represents a nearly 10x return on the exercise price. The magnitude of the position reduction (76%) and the decision to sell at $16.40 when options at $1.70 could have been held suggests the CLO may view current prices as attractive for profit-taking. Erasca is a clinical-stage biotech focused on RAS/MAPK pathway cancers — the dramatic stock appreciation from $1.70 to $16.40 likely reflects positive clinical data. The selling could be routine diversification after a significant run, or could signal the insider believes the risk/reward has shifted.

2. Brett Sandercock, CFO at ResMed Inc. (RMD) — $224,310

• Filing: Form 4, SEC EDGAR
• Date: April 1, 2026
• Transaction: Sold 1,000 shares at $224.31/share ($224,310 total)
• Post-transaction holdings: 83,495 shares remaining (a modest 1.2% reduction)
• The signal: A small, clean open-market discretionary sell by ResMed's CFO. The size is not alarming — it's a fraction of his $18.7M position — but CFO sells at large-cap medical device companies always warrant monitoring. ResMed has been a beneficiary of GLP-1 weight loss drug concerns (which proved overblown), and the stock is trading near its upper range. This looks more like incremental portfolio management than a conviction call.

3. Judson Gray Teekell, Director at Miami International Holdings (MIAX) — $108,000

• Filing: Form 4, SEC EDGAR
• Date: April 2, 2026
• Transaction: Sold 2,700 shares at $40.00/share ($108,000 total)
• Post-transaction holdings: 59,338 shares remaining (a 4.4% reduction)
• The signal: A director at the parent company of MIAX options exchange reducing exposure at a round number ($40). The exchange business has benefited from elevated volatility — VIX averaged 26+ over the past two weeks. Selling into strength at an options exchange as volatility begins to normalize is rational.

4. Douglas Bruggeman, CFO at REX American Resources (REX) — $90,880

• Filing: Form 4, SEC EDGAR
• Date: April 2, 2026
• Transaction: Sold 2,000 shares at $45.44/share ($90,880 total)
• Post-transaction holdings: 259,170 shares remaining (a tiny 0.8% reduction)
• The signal: A minimal trim by the CFO of this ethanol and renewable energy company. At $11.8M in remaining holdings, this is noise-level selling — likely routine liquidity needs rather than a conviction call.

5. Willis Lease Finance (WLFC) — $2,776,201 (Tax Withholding)

• Filing: Form 4, SEC EDGAR
• Date: April 1, 2026
• Insider: Scott B. Flaherty, EVP & CFO
• Transaction: 15,808 shares withheld at $175.62/share for tax obligations on vesting
• Post-transaction holdings: 81,392 shares ($14.3M at current price)
• The signal: While technically the largest dollar-value disposition today, this is mandatory tax withholding (code "F"), not a discretionary sell. The elevated per-share price of $175.62 for an aircraft leasing company reflects the sector's strong performance amid continued supply chain constraints in aerospace. Not informative as a directional signal.

Cluster Activity

|---|---|---|---|---|---|---|

SOPHiA GENETICS (SOPH) — The 7-insider simultaneous grant is the most notable cluster today, though it signals a new compensation cycle rather than buying conviction. When a Swiss-headquartered genomics analytics company awards equity to its entire C-suite on the same day, it typically reflects the board's annual equity refresh. President Ross Muken received the largest allocation at 431,211 ordinary shares plus 628,743 options — a substantial package suggesting Muken is viewed as a critical retention target. The simultaneous nature of these grants means SOPH's insiders are now heavily incentivized to drive stock performance from current levels.

Paysafe (PSFE) — Six executives all had restricted stock vest on April 1 with $2.79 million in aggregate tax withholding dispositions. CEO Bruce Lowthers alone had $1.09M withheld. This is a mechanical vesting cliff — the company went public via SPAC in 2021, and these multi-year RSU grants are now hitting their vesting schedules. The high volume of simultaneous vesting suggests a scheduled equity event, not coordinated selling. However, the fact that these insiders are not choosing to hold additional shares beyond the minimum (net vesting only, no supplemental open-market buys) is worth noting.

Root, Inc. (ROOT) — CEO Alexander Timm ($2.03M) and President/CTO Mahtiyar Bonakdarpour ($1.37M) both had performance-based RSUs vest and were hit with $3.41M in combined tax withholding at $43.26/share. Performance RSU vesting means ROOT hit predefined performance targets — a positive signal for the business. However, neither executive made any supplemental purchases, and the stock's rise from sub-$10 to $43+ creates natural selling pressure as vesting accelerates.

Sector Heat Map

|---|---|---|---|---|

Every sector shows a buy/sell ratio of 0.00 today. This is an exceptionally rare cross-sector unanimity in insider caution. The highest-value dispositions are concentrated in technology/software (driven by Paysafe's vesting cliff) and insurance/fintech (driven by Root's performance RSU vesting), but neither represents discretionary selling — these are mechanical tax withholding events.

The biotechnology/pharma sector stands out as the only area with meaningful discretionary selling — Erasca's CLO exercise-and-sell ($1.31M) and ResMed's CFO open-market sell ($224K) both represent voluntary decisions to reduce exposure at current prices.

Strategic Deep Dive

The most analytically significant transaction today isn't the largest by dollar value — it's the option exercise and immediate sale by Ebun Garner, Chief Legal Officer at Erasca, Inc. (ERAS), which tells a compelling story about insider behavior at inflection-point biotech companies.

The transaction in context. Garner exercised options on 80,000 shares at a strike price of $1.70 per share — options almost certainly granted when Erasca was a pre-revenue clinical-stage company — and sold all 80,000 shares at $16.40 on the same day. The gross proceeds of $1,312,000 against an exercise cost of $136,000 produced a net profit of $1,176,000, representing a 865% return. Post-transaction, Garner's direct holdings dropped from 105,076 shares to just 25,076 — a 76% reduction in her position.

Who is Ebun Garner? As CLO of Erasca, Garner sits at the intersection of regulatory strategy and corporate governance. Chief Legal Officers at biotech companies have unique visibility into: (a) the legal and regulatory landscape for their drug candidates, (b) upcoming SEC filings and disclosure obligations, (c) partnership and licensing discussions, and (d) any pending litigation or IP disputes. Garner's decision to lock in profits and dramatically reduce her position is notable because CLOs rarely trade for purely financial reasons — they are acutely aware of the optics and compliance implications.

The company backdrop. Erasca is focused on developing therapies targeting the RAS/MAPK pathway, which is implicated in approximately 30% of all human cancers. The stock's dramatic appreciation from the ~$1.70 option strike price to $16.40 current price suggests significant positive clinical developments. Biotech stocks that see this magnitude of appreciation typically have either: (a) reported positive Phase 2/3 data, (b) announced a partnership with a larger pharmaceutical company, or (c) received a breakthrough therapy designation from the FDA. The SIC code 2834 (Pharmaceutical Preparations) confirms Erasca is in the drug development business.

What could she know? (Speculation, clearly labeled.) There are several scenarios that could explain a CLO selling 76% of their position at a biotech that has seen 10x appreciation. The most benign explanation is simple diversification — Garner's options likely represented the majority of her net worth exposure to ERAS, and converting a concentrated position into cash is rational risk management regardless of outlook. A more cautious interpretation is that Garner may have visibility into upcoming data readouts or regulatory timelines that introduce binary risk — selling ahead of a catalyst (even one expected to be positive) locks in certainty over potential upside. The most concerning interpretation is that Garner sees regulatory or legal risks on the horizon that could pressure the stock.

Historical parallels. CLO sells at clinical-stage biotechs have mixed predictive value. When Moderna's CLO sold shares ahead of positive Phase 3 COVID vaccine data in 2020, the stock continued to rise dramatically. Conversely, when Valeant Pharmaceuticals insiders — including legal counsel — reduced positions in mid-2015, the stock collapsed 90% over the following year. The key differentiator is whether the selling is incremental (1-5% of position, routine) or substantial (>25% of position, potentially informative). Garner's 76% reduction falls firmly in the substantial category.

Three scenarios:

• Bull case (30% probability): Garner is simply diversifying after a life-changing windfall. Erasca's pipeline continues to advance, the stock reaches $25-30 within 6 months on positive data readouts, and the remaining 25,076 shares plus 280,000 options provide continued upside exposure. Garner still holds $411K in stock plus potentially millions in option value.
• Neutral case (45% probability): The stock trades sideways between $13-18 as the market digests recent data. Garner's sell was well-timed in the sense that she locked in profits at a local peak, but no fundamental deterioration occurs. The 280,000 options remaining ensure she still participates meaningfully in upside.
• Bear case (25% probability): Garner has visibility into upcoming regulatory or data risks — perhaps a clinical hold, a patent challenge, or disappointing interim data from an ongoing trial. The stock corrects to $8-12 within 3 months. Her decision to sell 76% of direct holdings at $16.40 looks prescient in hindsight.

The contrarian take. Most analysts will dismiss this as a routine exercise-and-sell by a mid-level executive locking in option profits. But the 76% position reduction by a Chief Legal Officer at a company whose stock has appreciated nearly 10x deserves more scrutiny than it will receive. CLOs don't typically trade this aggressively unless they've made a deliberate decision about their risk exposure. The fact that she retained 280,000 options provides a hedge — she still benefits from upside but has meaningfully de-risked her liquid position. Smart money watches when insiders sell the "house money" while keeping the lottery tickets.

Macro Context

The VIX at 24.54 remains meaningfully elevated above its long-run average of approximately 19, though it has declined sharply from the 30.61 reading on March 30 — a week-long 20% compression that typically signals the market is moving from fear to cautious complacency. For insider transaction analysis, an elevated but declining VIX creates an interesting dynamic: insiders who might have considered buying during the March 30 volatility spike may now feel they've "missed the dip" as the S&P 500 has recovered 3.8% to 6,582. This could partially explain today's zero-buy reading — the window of peak opportunity may have passed, and insiders are waiting for either a pullback to re-engage or for Q1 earnings visibility.

The Federal Funds Rate at 3.64% continues to reflect the Fed's measured easing cycle, which has brought rates down from their 2024 peaks but remains well above the zero-rate environment that fueled the 2020-2021 insider buying frenzy. Higher rates increase the opportunity cost of holding concentrated equity positions, which may be contributing to the steady drumbeat of mechanical selling (tax withholding on vesting) without corresponding new purchases. Insiders can earn 4%+ in money market funds, reducing the urgency to deploy capital into their own company's stock.

Today's aggregate buy/sell ratio of 0.00 compares to a historical average of approximately 0.35 and falls in the bottom 5th percentile of daily readings. However, context matters: we are now entering the Q1 2026 earnings quiet period, when many companies restrict insider trading in the 2-4 weeks before reporting. The concentration of mechanical transactions (RSU vesting, tax withholding, equity grants) and absence of discretionary purchases is consistent with quiet period restrictions rather than a coordinated bearish view. Investors should not over-interpret a single day's absence of buying during earnings blackout season.

The 10Y-2Y Treasury spread at 0.52 has normalized into positive territory after its historic inversion, suggesting the bond market is no longer pricing in imminent recession risk. Combined with the S&P 500 near its range highs and the VIX declining, the macro backdrop is one of cautious optimism — which ironically is often when insider buying dries up. Insiders tend to be most active as buyers during periods of acute pessimism (VIX >30, markets down >10%) and most active as sellers during periods of complacency. Today's filing data is consistent with that historical pattern.

What We'Re Watching Tomorrow

1. Erasca (ERAS) post-CLO-sell price action: Monitor whether additional Form 4 filings emerge from other ERAS insiders in the coming days. If the CLO's sell is followed by other executives reducing positions, the signal strengthens materially. Watch for any 8-K filings related to clinical data updates or regulatory correspondence.

2. Paysafe (PSFE) additional vesting tranches: With 6 executives hitting a vesting cliff simultaneously, there may be additional tranches converting in the coming days. Watch for any executives who choose to hold rather than have shares withheld — that would be a positive signal amid the mechanical selling.

3. SOPHiA GENETICS (SOPH) open-market activity: Seven executives just received substantial equity grants. If any of these insiders make supplemental open-market purchases on top of their grants within the next 30 days, that would be an exceptionally strong bullish signal — they already received free equity and chose to buy more with their own money.

4. Root (ROOT) Q1 earnings positioning: Both the CEO and President just had performance RSUs vest, confirming ROOT hit its targets. The stock is at $43.26 — watch for any additional Form 4 filings in the coming weeks, particularly any open-market buys that would signal continued confidence post-vesting.

5. Earnings quiet period deepening: As we move deeper into April, expect the dry spell in open-market purchases to continue as major companies enter their pre-earnings blackout windows. The absence of buying over the next 2 weeks should not be interpreted as bearish — it's structural. The key signal will be what happens when quiet periods lift in late April and May.

6. ResMed (RMD) follow-through: CFO Sandercock's discretionary sell at $224.31 may signal a view on near-term valuation. ResMed reports quarterly earnings in late April — watch for additional insider activity as the earnings date approaches. Any pre-earnings buying by other executives would counterbalance the CFO's sell.

7. China ADR executive compensation signals: JD.com and Alibaba both had RSU conversions today. With ongoing regulatory and geopolitical uncertainty around Chinese ADRs, monitor whether any executives at these companies make discretionary purchases — that would be a strong contrarian bullish signal given the overhang of delisting fears and trade tensions.